Skip to main content

Table 5 Base case cost-effectiveness results for 100,000 women over a lifetime time horizon with 100% coverage

From: Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada

Outcome HPV-16/18 AS04-adjuvanted vaccine plus screening (A) HPV-6/11/16/18 vaccine plus screening (B) Difference in outcomes (A – B)
Undiscounted    
CIN1 cases 8 217 9 020 −803
CIN2/3 cases 1 294 1 945 −651
Genital warts cases 9 688 2 755 6 933
Cervical cancer cases 113 161 −48
Cervical cancer deaths 38 54 −16
Life Years 7 163 635 7 163 268 367
Quality adjusted life years (QALY) 7 163 094 7 162 817 276
Lifetime cost of strategy $127 212 309 $129 344 736 -$2 132 427
Incremental cost per QALY gained    A Dominates B
Discounted outcomes    
Life Years 2 982 064 2 981 994 70
QALY 2 981 855 2 981 854 1
Lifetime cost of strategy $75 010 163 $75 693 270 -$683 107
Incremental cost per QALY gained    A Dominates B
  1. A – Vaccine A: HPV-16/18 AS04-adjuvanted vaccine.
  2. B - Vaccine B: HPV-6/11/16/18 vaccine.
  3. QALY – Quality Adjusted Life Year.
  4. Discount Rate – 3%.
Back to article page